Global Infectious Respiratory Disease Diagnostics Market Size study & Forecast, by Product Type (Instruments, Consumables, Services), by Sample Type (Saliva, Nasopharyngeal Swabs (NPS), Anterior Nasal Region, Blood, Others), by Technology (Immunoassay, Mo

Global Infectious Respiratory Disease Diagnostics Market Size study & Forecast, by Product Type (Instruments, Consumables, Services), by Sample Type (Saliva, Nasopharyngeal Swabs (NPS), Anterior Nasal Region, Blood, Others), by Technology (Immunoassay, Molecular Diagnostics, Microbiology, Other Technologies), by Application (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Tuberculosis, Streptococcus Testing, Other Respiratory Disease Testing) and Regional Analysis, 2022-2029

Global Infectious Respiratory Disease Diagnostics Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Infectious respiratory disease is caused by germs including bacteria, viruses, or further pathogenic microbes, which are generally spread via saliva and mucus when a person coughs, talks, sneezes, or laughs. Accordingly, infectious respiratory disease diagnostics help in the detection of germs in a patient with a compatible clinical illness. The increasing incidences of infectious respiratory diseases, rising number of initiatives by the government and non-profit organizations to provide advanced healthcare services, and rising penetration of molecular techniques are upsurging the market demand across the globe.

According to the World Health Organization (WHO), respiratory disease infection is considered the third major cause of death with approximately 3 million death per year (6% of global deaths), in which nearly 90% of COPD fatalities occur in those 70-year-old people from the low-and middle-income countries. Also, there are around 262 million patients were estimated to suffer from asthma, which commonly affects children. Therefore, the high prevalence of infectious respiratory diseases acts as a catalyzing factor for the market demand. Moreover, the increasing technological advancement in respiratory disease testing and growing R&D investments in respiratory disease testing are presenting lucrative prospects for market growth in the forthcoming years. However, high prices of diagnostic products and the presence of stringent regulatory frameworks are hindering market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Infectious Respiratory Disease Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the space in terms of revenue, owing to the availability of well-established healthcare facilities and increasing healthcare expenditure. Whereas, the Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as growing incidences of target diseases, increasing geriatric population, and rising emphasis on testing rates.

Major market players included in this report are:
Abbott
Thermo Fisher Scientific, Inc.
Koninklijke Philips N.V.
F. Hoffmann-La Roche Ltd.
bioMérieux SA
Bio-Rad Laboratories, Inc.
Quidel Corporation
Siemens Healthcare GmbH
Danaher
Qiagen
Recent Developments in the Market:
In September 2020, F. Hoffmann-La Roche Ltd. announced the introduction of Elecsys Anti-SARS-CoV-2 S antibody test in markets accepting CE marking. The company filed for EUA to launch its product across the United States and focus on the launch of multiplex diagnostic tests for COVID-19, RSV, and influenza.
Global Infectious Respiratory Disease Diagnostics Market Report Scope:
Historical DataCompanies Mentioned

Abbott
Thermo Fisher Scientific, Inc.
Koninklijke Philips N.V.
F. Hoffmann-La Roche Ltd.
bioMérieux SA
Bio-Rad Laboratories, Inc.
Quidel Corporation
Siemens Healthcare GmbH
Danaher
Qiagen

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.